Drug major Cipla on Monday said it has inked a pact with USbased Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of COVID19. The Mumbaibased company said it has signed a royaltyfree, nonexclusive voluntary licensing agreement with Eli Lilly for baricitinib.
Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of COVID-19. The Mumbai-based company said it has signed a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for baricitinib.
Recommended ArticlesView All
Biggest casualty of ending LTCG regime is not debt funds but the debt market
Mar 25, 2023 IST6 Min(s) Read
US Fed rate hike — willing to hit but afraid to wound
Mar 25, 2023 IST4 Min(s) Read
Withering Weather: Experts see erratic rains to spell higher food prices and tougher inflation ahead
Mar 24, 2023 IST4 Min(s) Read
Decoding Finance Bill proposals for debt funds: What remains and what changes
Mar 24, 2023 IST3 Min(s) Read
Baricitinib has already received a restricted emergency use approval by the Central Drugs Standard Control Organisation (CDSCO), Ministry of Health, India, for use in combination with remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). This collaboration is a step further in the company’s efforts to enhance access to critical treatments for patients affected by the pandemic, Cipla said in a statement. The company will leverage its extensive distribution footprint to make this therapy accessible to more patients and markets, it added.
Through the pandemic, Cipla has been at the forefront of COVID care and our partnership with Lilly is a demonstration of our unwavering commitment to care towards patients impacted by COVID-19,” Cipla Ltd MD and Global CEO Umang Vohra noted. Cipla had last year launched a generic version of antiviral drug remdesivir to treat COVID-19 patients. The drug firm had also introduced antibody detection kits for COVID-19 in the country under the brand name ’ELIFast’ in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).
Amid spiralling cases of COVID-19 in the country amid the second wave, drug firms have been collaborating to come out with drugs to treat the highly infectious disease.
Follow our LIVE COVID-19 blog for the latest
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!